Locations:
Search IconSearch
November 26, 2021/Pediatrics/Ophthalmology

Intraocular Lens Implants in Infants With Bilateral Cataracts

Does the age at surgery and the use of intraocular lens (IOL) implants influence outcomes?

650×450-Outcomes-of-Bilateral-Cataract-Surgery-172342643

The optimal age for the use of intraocular lens (IOL) implants in a child who has bilateral cataracts and is undergoing cataract surgery is not well-described. A recent study evaluates data from a cataract surgery registry to understand possible associations between age during the procedure and adverse events.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Elias Traboulsi, MD, M.Ed, pediatric ophthalmologist at Cleveland Clinic Children’s, is a coauthor on the study.

Leveraging the Toddler Aphakia and Pseudophakia Study (TAPS) registry

The Toddler Aphakia and Pseudophakia Study (TAPS) registry was established to investigate the outcomes of cataract surgery in infants who were operated on by a group of surgeons from 10 institutions in the U.S., the same group who had previously participated in the Infant Aphakia Treatment Study (IATS). The latter study compared the outcomes of infants under the age of 7 months whose unilateral cataracts were removed and they were either 1) left aphakic and wore a contact lens or 2) they received an IOL at the time of surgery.

Outcomes and adverse events in children undergoing bilateral cataract surgery

In this study, the research team investigated outcomes and adverse events in children ages 7 to 24 months, enrolled in the TAPS registry between 2004 and 2010, who underwent bilateral cataract surgery, with or without IOL placement, and had five years of follow-up. The sample size included 76 eyes of 40 children, and 11 months was the median age at the time of surgery.

Key findings

  • Approximately two-thirds received a primary IOL.
  • Opacification of the visual axis occurred in only 7.5% of eyes and only in eyes with IOLs (odds ratio, 6.10; P = 0.005).
  • While glaucoma was suspected in 2.5% of eyes, no child developed glaucoma.
  • Adverse events, including glaucoma suspect status or opacification of the visual axis and reoperations, were as frequent as those in patients with unilateral cataracts in the TAPS cohort.
  • When these outcomes were compared to those of infants operated on for bilateral cataracts between 1 and 7 months of age, the incidence of adverse events and glaucoma or glaucoma suspect correlated strongly with age at surgery (P = 0.011/0.004) and glaucoma correlated with microcornea (P = 0.040) but not with IOL insertion (P = 0.15).

Advertisement

The takeaway message

The data from this study indicate a low rate of visual axis opacification (VAO) and very rare glaucoma, as opposed to infants with cataracts operated on earlier than 7 months of age. Primary IOL implantation was chosen by surgeons in most infants in the 7 to 24 months group. This study further supports that the use of an IOL increases the risk of VAO irrespective of patients’ age at the time of surgery.

Reference

Bothun ED, Wilson ME, Yen KG, Anderson JS, Weil NC, Loh AR, Morrison D, Freedman SF, Plager DA, Vanderveen DK, Traboulsi EI, Hodge DO, Lambert SR; Toddler Aphakia and Pseudophakia Study. Outcomes of Bilateral Cataract Surgery in Infants 7 to 24 Months of Age Using the Toddler Aphakia and Pseudophakia Treatment Study Registry. Ophthalmology. 2021 Feb;128(2):302-308. doi: 10.1016/j.ophtha.2020.07.020. Epub 2020 Jul 15. PMID: 32679160.

Advertisement

Related Articles

Dr. Weaver smiling with a pediatric patient
February 6, 2026/Pediatrics/Urology
Rethinking the Diagnostic Paradigm for Pediatric Kidney Abnormalities

One pediatric urologist’s quest to improve the status quo

MRI images of pediatric kidney disease
February 3, 2026/Pediatrics/Nephrology
Developing Imaging Biomarkers for Autosomal Recessive Polycystic Kidney Disease

Overcoming barriers to implementing clinical trials

gene editing
Novel Gene Editing Therapy for Sickle Cell Disease Continues to Free Patients From Severe Vaso-Occlusive Pain

Interim results of RUBY study also indicate improved physical function and quality of life

Wearable sensor on the chest of a baby
January 22, 2026/Pediatrics/Cardiology
Wearable Sensors May Enable Everyday Monitoring of Congenital Heart Disease

Innovative hardware and AI algorithms aim to detect cardiovascular decline sooner

Dr. Guelfand in the operating room
January 14, 2026/Pediatrics
First Magnetic-Assisted Cholecystectomy Performed in US for a Pediatric Patient

The benefits of this emerging surgical technology

Child and caregiver hands on top of hospital bed
Palliative Care Addresses an Unmet Need in Sickle Cell Disease

Integrated care model reduces length of stay, improves outpatient pain management

Dr. Tretter in conversation with Dr. Najm
December 4, 2025/Pediatrics/Cardiac Surgery
A New Era: What 3D Visualization of the Conduction System Means for Specialists

A closer look at the impact on procedures and patient outcomes

Dr. Najm with colorful 3D-printed heart model
November 24, 2025/Pediatrics/Cardiac Surgery
Ventricular Switch: What We’ve Learned From Our Growing Patient Cohort

Experts advise thorough assessment of right ventricle and reinforcement of tricuspid valve

Ad